IRONWOOD PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $6.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- IRONWOOD PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $6.39M.
- IRONWOOD PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was $43.00K.
- IRONWOOD PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2020 was -$144.00K.
- IRONWOOD PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2019 was -$1.20M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $6.39M 10-K · filed 2026-02-26 |
| 2021-12-31 | $43.00K 10-K · filed 2022-02-18 |
| 2020-12-31 | -$144.00K 10-K · filed 2022-02-18 |
| 2019-12-31 | -$1.20M 10-K · filed 2022-02-18 |
| 2018-12-31 | -$494.00K 10-K · filed 2021-02-17 |
| 2017-12-31 | $9.00K 10-K · filed 2020-02-13 |
| 2016-12-31 | $3.53M 10-K · filed 2019-02-25 |
| 2015-12-31 | $3.82M 10-K · filed 2018-02-22 |
| 2014-12-31 | $3.58M 10-K · filed 2017-02-22 |
| 2013-12-31 | $3.83M 10-K · filed 2016-02-19 |
| 2012-12-31 | $3.53M 10-K · filed 2015-02-18 |
| 2011-12-31 | $2.10M 10-K · filed 2014-02-07 |
| 2010-12-31 | -$243.00K 10-K · filed 2013-02-21 |
| 2009-12-31 | $1.30M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |